The chart below shows how CNC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CNC sees a +0.12% change in stock price 10 days leading up to the earnings, and a +0.47% change 10 days following the report. On the earnings day itself, the stock moves by +1.18%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Earnings Power Demonstrated: Adjusted diluted EPS for Q4 2024 was reported at $0.80, with a full year adjusted diluted EPS of $7.17, exceeding previous guidance and demonstrating strong earnings power.
Revenue Guidance Increase: Centene raised its full year 2025 revenue guidance by $4 billion, now expecting total revenue between $158 billion and $160 billion, reflecting better-than-expected results during the Medicare annual enrollment period and Medicaid program expansion.
Medicaid Membership Stabilization: Medicaid membership is projected to stabilize at approximately 13 million members, with a mid-4% composite rate adjustment achieved, supporting a return to target Medicaid margins.
Medicare Quality Improvement: In the Medicare segment, 55% of members are now associated with plans rated 3.5 stars or better, a significant increase from 23% last year, indicating improved quality and performance metrics.
Marketplace Segment Growth: The marketplace segment, Ambetter, is expected to peak at over 5 million members, with effectuated enrollment showing strong retention and demographic stability, positioning the company well for continued growth.
Negative
Q4 Adjusted EPS Decline: Adjusted diluted EPS for Q4 was $0.80, which is lower than expected, indicating potential challenges in profitability.
Higher Medical Costs Impact: The consolidated HBR was reported at 89.6%, with a full year consolidated HBR of 88.3%, suggesting higher medical costs than anticipated.
Operational Cash Flow Decline: Cash flow from operations was only $154 million for the full year, significantly lower than expected due to timing issues with pharmacy rebate collections and state premium payments receivable.
Medicaid HBR Increase: Medicaid HBR increased to 93.4%, up 30 basis points from the previous year, indicating rising medical costs and potential margin pressure.
Prior Year Development Impact: The company faced a $400 million prior year development (PYD) adjustment, which could negatively impact future earnings if trends do not improve.
Earnings call transcript: Centene Q4 2024 beats EPS forecast, stock dips
CNC.N
-7.22%